These data-driven biomedical methods may pinpoint a yet-to-be-defined Achilles’ heel of cSCC, in line with the effects of trastuzumab (human epidermal growth factor receptor 2 inhibitor) in breast cancer [111], cetuximab (EGFR inhibitor) in colorectal cancer [112], imatinib (RTKI) in dermatofibrosarcoma protuberans [113] and dabrafenib (BRAF inhibitor)/trametinib (MEK inhibitor) in malignant melanoma [114]. This evidence concerns the gene BRAF and melanoma.